Affiliation:
1. First Department of Surgery, University of Fukui, 23-3 Eiheiji-cho, Yoshida-gun, Fukui 9101193, Japan
Abstract
Multidisciplinary treatment for colorectal cancer (CRC) has undergone significant advances, and molecularly targeted drugs have substantially improved patient prognosis. However, one problem with current molecularly targeted therapeutics is that they must be used in combination with anticancer agents. New molecular targeted therapies that can be used alone are needed. We have previously identified prokineticin1 (PROK1) factor as a therapeutic potential target for CRC. PROK1 factor is involved in the angiogenesis of tissues surrounding CRC tumors. Additionally, PROK1 receptors 1 and 2 are expressed in CRC cell lines, playing roles in cell proliferation via an autocrine mechanism and in the signaling system. In this study, a liver metastasis mouse model was developed using human colorectal cancer cell lines, and mice were divided into anti-PROK1 antibody administration and control groups. Mice were treated intraperitoneally with antibodies or phosphate-buffered saline (control) every three days. The number, size, and cell proliferation ability of metastatic lesions were analyzed. Our results suggested that the number, size, and cancer cell proliferation ability of metastatic lesions decreased, and the survival time significantly increased in the antibody-treated group compared to those in the control group. Thus, the anti-PROK1 antibody therapy suppressed the cell proliferation ability of liver metastatic lesions in a CRC mouse model, suggesting its potential as a novel treatment strategy.
Funder
Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science
Subject
Microbiology (medical),Molecular Biology,General Medicine,Microbiology
Reference21 articles.
1. The implications of angiogenesis for the biology and therapy of cancer metastasis;Fidler;Cell,1994
2. Global cancer statistics;Jemal;CA Cancer J. Clin.,2011
3. Siegel, R., and Jemal, A. (2010). Cancer Facts & Figures’, Health Policy, American Cancer Society.
4. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for treatment of colorectal cancer;Watanabe;Int. J. Clin. Oncol.,2012
5. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: Recommendations from an expert panel;Nordlinger;Ann. Surg.,2006